NCI clincial trial: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi... - Full Text View - ClinicalTrials.gov Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, January 26, 2010

NCI clincial trial: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi... - Full Text View - ClinicalTrials.gov



Drug: VELCADE, PS-341 (Bortezomib, NSC #681239) Drug: ZACTIMA (Vandetanib) (ZD6474) Phase I Phase II

Breast Cancer Colon Cancer Prostate Cancer Lung Cancer Adrenal Cancer Renal Cancer Gastric Cancer Ovarian Cancer Cervical Cancer Thyroid Cancer Sarcoma
Blogger
add your opinions , , , , ,

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments ( Atom )